Early risk stratification of unstable angina/non-Q myocardial infarction: Biochemical markers of coronary thrombosis

International Journal of Cardiology

Volumn 68, Issue SUPPL. 1, 1999, Pages

  Galvani, Marcello ^a,b   Ferrini, Donatella ^a,b   Ottani, Filippo ^a,c   Eisenberg, Paul R ^d  

^a Cardiovascular Research Unit   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c Pneumology Unit   (Italy)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; THROMBIN ANTITHROMBIN COMPLEX;

ANGIOCARDIOGRAPHY; ANTIGEN ANTIBODY REACTION; CORONARY ARTERY THROMBOSIS; CROSS LINKING; HEART INFARCTION; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; REVIEW; RISK ASSESSMENT; UNSTABLE ANGINA PECTORIS;

EID: 0033541544     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(98)00292-7     Document Type: Article

References (32)

1. Chesebro J, Rauch U, Fuster V, Badimon J. Pathogenesis of thrombosis in coronary artery disease. Haemostasis 1997;27(Suppl 1):12-8.
2. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation 1998;97:1195-206.
3. Wallentin L. Low molecular weight heparins: a valuable tool in the treatment of acute coronary syndromes. Eur Heart J 1996;17:1470-6.
4. Van de Werf F. Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes. Thromb Haemost 1997;78:210-3.
5. Freeman MR, Williams AE, Chisholm RJ, Armstrong PW. Intracoronary thrombus and complex morphology in unstable angina. Relation to timing of angiography and in-hospital cardiac events. Circulation 1989;80:17-23.
6. Tripodi A, Chantarngkul V, Bottasso B, Mannucci PM. Poor comparability of prothrombin fragment 1+2 values measured by two commercial ELISA methods: influence of different anticoagulants and standards. Thromb Haemost 1994;71:605-8.
7. Seitz R, Blanke H, Pratorius G, Strauer BE, Egbring R. Increased thrombin activity during thrombolysis. Thromb Haemost 1988;59:541-2.
8. Koehn JA, Canfield RE. Purification of human fibrinopeptides by high-performance liquid chromatography. Anal Biochem 1981;116:349-56.
9. Eisenberg PR. Novel antithrombotic strategies for the treatment of coronary artery thrombosis: a critical appraisal. J Thromb Thrombol 1995;1:237-50.
10. Wilf J, Minton AP. Soluble fibrin-fibrinogen complexes as intermediates in fibrin gel formation. Biochemistry 1986;25:3124-33.
11. Kruskal JB, Commeford PJ, Franks JJ, Kirsch RE. Fibrin and fibrinogen-related antigens in patients with unstable coronary artery disease. N Engl J Med 1987;317:1361-5.
12. Lee LV, Ewald G, McKenzie C, Eisenberg PR. The relationship of soluble fibrin and cross-linked fibrin degradation products to the clinical course of myocardial infarction. Arterioscler Thromb 1997;17:628-33.
13. Takada Y, A.T. Measurements of the concentration of free plasminogen activator inhibitor (PAI-1) and its complex with tissue plasminogen activator in human plasma. Thromb Res 1988;(Suppl VIII): 15-22.
14. Takada A, Shizume K, Ozawa T, Takahashi S, Takada Y. Characterization of various antibodies against tissue plasminogen activator using highly sensitive enzyme immunoassay. Thromb Res 1986;42:63-72.
15. Hamsten A, Walldius G, Szamosi A, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;ii:3-9.
16. Meade TW, Ruddock V, Stirling Y, Charkrabarti R, Miller GJ. Fibrinolytic activity, clotting, factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993;342:1076-9.
17. Ridker PM, Vaughan DE, Stampfer MJ, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165-8.
18. Montes R, Paramo JA, Angles-Cano E, Rocha E. Development and clinical application of a new ELISA assay to determine plasmin-alpha 2-antiplasmin complexes in plasma. Br J Haematol 1996;92:979-85.
19. Rylatt DB, Blake AS, Cottis DA, et al. An immunoassay for human D-dimer using monoclonal antibodies. Thromb Res 1983;31:767-78.
20. Eisenberg PR, Rylatt DB, Rusticali F, Ferrini D, Ottani F, Galvani M. The importance of antibody specificity in measuring cross-linked fibrin degradation products by ELISA. Blood Coag Fibrinol 1997;8:105-13.
21. Declerck PJ, Mombaerts P, Holvoet P, De Mol M, Collen D. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis. Thromb Haemost 1987;58:1024-9.
22. Koopman MMW, Brandjes DPM, Beek EJR, Turkstra, F, Buller, HR. Sensitivity and specificity of a bed-side whole blood latex D-dimer assay (SimpliRED) in outpatients with deep vein thrombosis. Thromb Haemost 1995;73:1100 (abstract).
23. Eisenberg PR, Kenzora JL, Sobel BE, Ludbrook PA, Jaffe AS. Relation between ST segment shifts during ischemia and thrombin activity in patients with unstable angina. J Am Coll Cardiol 1991;18:898-903.
24. Wilensky RL, Bourdillon PDV, Vix VA, Zeller JA. Intracoronary artery thrombus formation in unstable angina: a clinical, biochemical, and angiographic correlation. J Am Coil Cardiol 1993;21:692-9.
25. Meade TW, Miller GJ, Rosenberg RD. Characteristics associated with the risk of arterial thrombosis and the prethrombotic state. In: Fuster V, Verstraete M., editors. Thrombosis in cardiovascular disorders. Philadelphia: W.B. Saunders Company, 1992. p. 79-97.
26. Ardissino D, Merlini P, Gamba G, et al. Thrombin activity and early outcome in unstable angina pectoris. Circulation 1996;93:1634-9.
27. Granger C, Becker R, Tracy R, et al. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1998;31:497-505.
28. Galvani M, Ottani F, Ferrini D, et al. Soluble fibrin as a marker of increased risk in acute coronary syndromes. J Am Coll Cardiol 1997;29:382A.
29. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61-8.
30. Eisenberg PR, Sherman LA, Perez J, Jaffe AS. Relationship between elevated plasma levels of cross-linked fibrin degradation products (XL-FDP) and the clinical presentation of patients with myocardial infarction. Thromb Res 1987;46:109-20.
31. Galvani M, Ottani F, Puggioni R, et al. Value of a new bedside D-dimer assay for early risk stratification of patients with acute coronary syndromes. Circulation 1996;94:I-133.
32. Galvani M, Ottani F, Ferrini D, et al. High risk of coronary events in patients with acute coronary syndromes and elevated troponin I is identified by concurrent elevations of cross-linked fibrin degradation products. Eur Heart J 1997;18:394.